A phase II, open-label study of the clinical activity, safety, and tolerability of lapatinib in combination with bevacizumab in subjects with advanced or metastatic ErbB2-overexpressing breast cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Lapatinib (Primary) ; Bevacizumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 25 Jun 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 06 Jul 2017 Planned End Date changed from 21 Dec 2017 to 31 Dec 2018.
- 25 Jan 2017 Planned End Date changed from 1 Mar 2017 to 21 Dec 2017.